← Research library

Cerebrolysin for vascular dementia.

Review of earlier studies · 2019

What was studied
Six vascular-dementia trials; 597 participants
Main finding
Cochrane found possible cognitive and global-function signals but a weak, very low-certainty evidence base.

Cognition · SMD 0.36; 95% CI 0.13–0.58 · Three studies, 420 people; very low certainty

Reported findings and study design

Vascular-dementia review: six trials, 597 participants; no new eligible studies in the update. Follow-up 15 days–three years.

Population or model Six vascular-dementia trials; 597 participants

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
CognitionSMD 0.36; 95% CI 0.13–0.58Three studies, 420 people; very low certainty
Global-function responseRR 2.69; 95% CI 1.82–3.98Two studies, 379; very low certainty
Adverse eventsRR 0.91; 95% CI 0.29–2.85Two studies, 379; very low certainty
MortalityOne trial reported no deathsOther trials did not supply usable mortality data

Heterogeneous, high-risk-of-bias studies. Scale response is distinct from preventing dementia or mortality.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • High risk of bias, heterogeneity and potentially clinically small effects. No quality-of-life or caregiver-burden data; industry support where funding was reported.

Source details

Journal publication

Citation and indexed abstract checked. Full methods, funding and risk of bias have not been comprehensively appraised.

Sources checked

Citation

ReviewEnglish abstract

Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. The Cochrane database of systematic reviews

Study source ↗ · DOI 10.1002/14651858.cd008900.pub3 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards